Literature DB >> 19836998

Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?

Bo Nilsson1, Olle Korsgren, John D Lambris, Kristina Nilsson Ekdahl.   

Abstract

Biomaterials (e.g. polymers, metals, or ceramics), cell and cell cluster (e.g. pancreatic islets) transplantation are beginning to offer novel treatment modalities for some otherwise intractable diseases. The innate immune system is involved in incompatibility reactions that occur when biomaterials or cells are introduced into the blood circulation. In particular, the complement, coagulation and contact systems are involved in the recognition of biomaterials and cells, eliciting activation of platelets and leukocytes. Such treatments are associated with anaphylactoid and thrombotic reactions, inflammation, and rejection of biomaterials and cells, leading to treatment failures and adverse reactions. We discuss here the new technologies that are being developed to shield the biomaterial and cell surfaces from recognition by the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19836998      PMCID: PMC2818156          DOI: 10.1016/j.it.2009.09.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  50 in total

1.  Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation.

Authors:  H Johansson; M Goto; D Dufrane; A Siegbahn; G Elgue; P Gianello; O Korsgren; B Nilsson
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

2.  Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation.

Authors:  Sanja Cabric; Javier Sanchez; Torbjörn Lundgren; Aksel Foss; Marie Felldin; Ragnar Källen; Kaija Salmela; Annika Tibell; Gunnar Tufveson; Rolf Larsson; Olle Korsgren; Bo Nilsson
Journal:  Diabetes       Date:  2007-05-31       Impact factor: 9.461

Review 3.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation.

Authors:  Lorenzo Piemonti; Biagio Eugenio Leone; Rita Nano; Alessandra Saccani; Paolo Monti; Paola Maffi; Giancarlo Bianchi; Antonio Sica; Giuseppe Peri; Raffaella Melzi; Luca Aldrighetti; Antonio Secchi; Valerio Di Carlo; Paola Allavena; Federico Bertuzzi
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

5.  Encapsulation of islets with ultra-thin polyion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane.

Authors:  Suguru Miura; Yuji Teramura; Hiroo Iwata
Journal:  Biomaterials       Date:  2006-08-17       Impact factor: 12.479

6.  Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.

Authors:  E A Ryan; J R Lakey; R V Rajotte; G S Korbutt; T Kin; S Imes; A Rabinovitch; J F Elliott; D Bigam; N M Kneteman; G L Warnock; I Larsen; A M Shapiro
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

Review 7.  Pig islet xenotransplantation into non-human primate model.

Authors:  Denis Dufrane; Pierre Gianello
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

8.  Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats.

Authors:  Juan L Contreras; Christopher Eckstein; Cheryl A Smyth; Marty T Sellers; Mario Vilatoba; Guadalupe Bilbao; Firoz G Rahemtulla; Carlton J Young; J Anthony Thompson; Irshad H Chaudry; Devin E Eckhoff
Journal:  Diabetes       Date:  2003-12       Impact factor: 9.461

9.  Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation.

Authors:  Jenny Tjernberg; Kristina N Ekdahl; John D Lambris; Olle Korsgren; Bo Nilsson
Journal:  Transplantation       Date:  2008-04-27       Impact factor: 4.939

10.  A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.

Authors:  Yuxiang Huang; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more
  41 in total

Review 1.  Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain.

Authors:  Esther S O'Sullivan; Arturo Vegas; Daniel G Anderson; Gordon C Weir
Journal:  Endocr Rev       Date:  2011-09-27       Impact factor: 19.871

Review 2.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

Review 3.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

4.  Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.

Authors:  Christine T N Pham; Lynne M Mitchell; Jennifer L Huang; Christopher M Lubniewski; Otto F Schall; J Kendall Killgore; Dipanjan Pan; Samuel A Wickline; Gregory M Lanza; Dennis E Hourcade
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

5.  Blood protein-polymer adsorption: implications for understanding complement-mediated hemoincompatibility.

Authors:  Anna E Engberg; Jenny P Rosengren-Holmberg; Hui Chen; Bo Nilsson; John D Lambris; Ian A Nicholls; Kristina N Ekdahl
Journal:  J Biomed Mater Res A       Date:  2011-02-11       Impact factor: 4.396

Review 6.  Mesh biocompatibility: effects of cellular inflammation and tissue remodelling.

Authors:  Karsten Junge; Marcel Binnebösel; Klaus T von Trotha; Raphael Rosch; Uwe Klinge; Ulf P Neumann; Petra Lynen Jansen
Journal:  Langenbecks Arch Surg       Date:  2011-04-01       Impact factor: 3.445

7.  Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Authors:  Guido Moll; Jessica J Alm; Lindsay C Davies; Lena von Bahr; Nina Heldring; Lillemor Stenbeck-Funke; Osama A Hamad; Robin Hinsch; Lech Ignatowicz; Matthew Locke; Helena Lönnies; John D Lambris; Yuji Teramura; Kristina Nilsson-Ekdahl; Bo Nilsson; Katarina Le Blanc
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

8.  Magnetization transfer contrast MRI for non-invasive assessment of innate and adaptive immune responses against alginate-encapsulated cells.

Authors:  Kannie W Y Chan; Guanshu Liu; Peter C M van Zijl; Jeff W M Bulte; Michael T McMahon
Journal:  Biomaterials       Date:  2014-06-13       Impact factor: 12.479

9.  Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response.

Authors:  Matthew J Webber; John B Matson; Vibha K Tamboli; Samuel I Stupp
Journal:  Biomaterials       Date:  2012-06-28       Impact factor: 12.479

Review 10.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.